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Abstract
Objective
To assess the association of baseline imaging markers of cerebral small vessel disease (SVD)
and brain frailty with clinical outcome after acute stroke in the Eﬃcacy of Nitric Oxide in Stroke
(ENOS) trial.
Methods
ENOS randomized 4,011 patients with acute stroke (<48 hours of onset) to transdermal
glyceryl trinitrate (GTN) or no GTN for 7 days. The primary outcome was functional outcome
(modiﬁed Rankin Scale [mRS] score) at day 90. Cognition was assessed via telephone at day
90. Stroke syndrome was classiﬁed with the Oxfordshire Community Stroke Project classiﬁ-
cation. Brain imaging was adjudicated masked to clinical information and treatment and
assessed SVD (leukoaraiosis, old lacunar infarcts/lacunes, atrophy) and brain frailty (leu-
koaraiosis, atrophy, old vascular lesions/infarcts). Analyses used ordinal logistic regression
adjusted for prognostic variables.
Results
In all participants and those with lacunar syndrome (LACS; 1,397, 34.8%), baseline CT imaging
features of SVD and brain frailty were common and independently associated with unfavorable
shifts in mRS score at day 90 (all participants: SVD score odds ratio [OR] 1.15, 95% conﬁdence
interval [CI] 1.07–1.24; brain frailty score OR 1.25, 95% CI 1.17–1.34; those with LACS: SVD
score OR 1.30, 95% CI 1.15–1.47, brain frailty score OR 1.28, 95% CI 1.14–1.44). Brain frailty
was associated with worse cognitive scores at 90 days in all participants and in those with LACS.
Conclusions
Baseline imaging features of SVD and brain frailty were common in lacunar stroke and all
stroke, predicted worse prognosis after all acute stroke with a stronger eﬀect in lacunar stroke,
and may aid future clinical decision-making.
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Cerebral small vessel disease (SVD) is a common cause of
lacunar ischemic stroke, hemorrhagic stroke, vascular cogni-
tive impairment, and dementia.1 The pathophysiology of SVD
diﬀers from that of other stroke subtypes and is thought to
reﬂect intrinsic damage to small perforating arterioles man-
ifested as endothelial dysfunction, blood-brain barrier break-
down, and inﬂammation.2 Imaging markers of SVD include
white matter hyperintensities or leukoaraiosis, microbleeds,
prominent perivascular spaces, and lacunes, in addition to
acute lacunar infarcts and intracerebral hemorrhage.3 All are
visible on MRI, while microbleeds and perivascular spaces are
not visible on CT scanning.
Recently, instead of considering each individual SVD fea-
ture separately, a summary score of SVD features was as-
sociated with risk factors,4 cognition,5 and mobility.6
Several large trials have reviewed the association between
imaging markers of SVD and outcome.7–9 Some analyses
focused on features seen on MRI,4,9 while others identiﬁed
general prestroke features visible on CT (including SVD
speciﬁc) that were associated independently with poor
outcome (leukoaraiosis, cerebral atrophy, and old vascular
lesions/infarcts), suggesting that these might represent
markers of brain frailty.7
Few trials or large observational studies have focused on
outcomes after acute lacunar stroke, largely because such
patients have better clinical outcomes compared to patients
with other ischemic stroke subtypes.10–12 Three trials have
reported outcomes after acute lacunar stroke in a total of 835
participants,10,12 with 422 being the largest trial population of
patients with acute lacunar stroke to date.12 There are also
modest studies using nonrandomized data from thrombolysis
registers.10,11 Although the Secondary Prevention of Small
Subcortical Strokes (SPS3) trial recruited 3,020 patients up to
180 days after symptomatic lacunar stroke, it does not provide
data on outcome after acute lacunar stroke.13 In contrast, the
Eﬃcacy of Nitric Oxide in Stroke (ENOS) trial assessed the
safety and eﬃcacy of transdermal glyceryl trinitrate (GTN) in
4,011 patients with acute stroke, of which a large proportion
(1,397, 35%) were of the lacunar subtype.14
The aims of the present analysis were to assess the inﬂuence
of imaging markers of SVD and brain frailty at baseline on
functional and cognitive outcome in patients with acute
stroke, particularly lacunar stroke, in the ENOS trial. We
sought to test the following hypotheses: (1) baseline imag-
ing markers of SVD will be more prevalent in those with
lacunar than nonlacunar stroke; (2) increased baseline SVD
score will be associated with poor functional and cognitive
outcomes after acute lacunar stroke; and (3) increased
baseline brain frailty score will be associated with poor
functional and cognitive outcomes after acute lacunar and
nonlacunar stroke.
Methods
Details on the ENOS trial protocol, statistical analysis plan,
baseline characteristics, and main results have been published
previously.14–17 In summary, ENOS recruited 4,011 patients
in 173 centers in 23 countries within 48 hours of stroke onset
with high systolic blood pressure (140–220 mm Hg) and
randomized them to GTN 5 mg patch or no patch for 7 days.
Participants on antihypertensive medication before their in-
dex event were also randomized to continue or stop these
medications for 7 days.
Standard protocol, approvals, registrations,
and patient consents
Patients or relatives/caregivers provided written consent.
ENOS was registered (ISRCTN99414122) and approved by
ethics committees/competent authorities in all participating
countries.
Study population
Stroke syndrome was assessed at baseline with the Oxford-
shire Community Stroke Project (OCSP) clinical classiﬁ-
cation.18 We incorporated imaging ﬁndings to create
a hierarchy of increasing speciﬁcity of deﬁnitions of acute
lacunar stroke19 as follows: patients without lacunar syn-
drome (LACS; n = 2,614); patients with clinical LACS (n =
1397), including ischemic and hemorrhagic stroke; patients
with LACS with a compatible scan (n = 623), that is, LACS
with an adjudicated acute lacunar infarct or, if no acute in-
farct visible, then no alternative pathology seen to explain
the presentation; and patients with LACS with corre-
sponding acute lacunar infarction on imaging (n = 143).
Therefore, LACS with corresponding acute lacunar in-
farction is a subset of LACS with compatible scan, and both
are subsets of LACS.
Glossary
CI = conﬁdence interval; ENOS = Eﬃcacy of Nitric Oxide in Stroke; GTN = glyceryl trinitrate; IST-3 = Third International
Stroke Trial; LACI-2 = Lacunar Intervention Trial-2; LACS = lacunar syndrome; MD = mean diﬀerence; mRS = modiﬁed
Rankin Scale; OCSP = Oxfordshire Community Stroke Project; OR = odds ratio; RIGHT-2 = Rapid Intervention With
Glyceryl Trinitrate in Hypertensive Stroke Trial–2; SPS3 = Secondary Prevention of Small Subcortical Strokes; SSS =
Scandinavian Stroke Scale; STIR = Stroke Imaging Repository; SVD = small vessel disease; t-MMSE = telephone Mini-Mental
State Examination; TICS-M = modiﬁed Telephone Interview for Cognitive Status; VISTA = Virtual International Stroke Trials
Archive.
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Imaging
CT or MRI brain scans were performed at baseline, usually
before randomization. A second CT brain scan was performed
at day 7 (end of treatment) when feasible. Scans were sent to
the coordinating center and adjudicated with a set proforma7
by trained neuroradiologists or neurologists (A.A., J.L.B.,
L.A.C., A.C., R.A.D., P.K., J.M.W.) blinded to clinical details
and randomization allocation. These assessments docu-
mented the location, size, and swelling associated with any
acute ischemic or hemorrhagic lesion and the presence of
prestroke changes, including atrophy, leukoaraiosis, and old
vascular lesions. Atrophy was assessed separately in cortical
and central regions, deﬁned as 0 = absent, 1 =moderate, or 2 =
severe, and compared against a standard template,7 thus
providing a maximum score of 4. Leukoaraiosis was assessed
separately in anterior and posterior brain regions,20 deﬁned as
0 = no lucency, 1 = lucency restricted to region adjoining
ventricles, or 2 = lucency covering entire region from lateral
ventricle to cortex, providing a maximum score of 4. Old
vascular lesions/infarcts were classiﬁed by location (e.g.,
cortical, striatocapsular, border zone, lacunar).
In addition to individual imaging markers of SVD, we applied
scores adapted for CT scanning as follows: SVD score com-
prises 1 point each for severe leukoaraiosis (score = 2 ante-
riorly and/or posteriorly as above), severe atrophy (score = 2
cortically and/or centrally), and any old lacunar infarcts/
lacunes (maximum 3 of 3).9 SVD score excluding atrophy
(maximum 2 of 2) was also assessed because atrophy, al-
though related, is not speciﬁc to SVD. Brain frailty score
comprises 1 point each for leukoaraiosis (score = 1 or 2 an-
teriorly and/or posteriorly), cerebral atrophy (score = 1 or 2
cortically and/or centrally), and old vascular lesions/infarcts
(maximum 3 of 3). Although there is no accepted deﬁnition of
brain frailty, we used the individual features on both CT and
MRI included in the Third International Stroke Trial, which
were individually shown to be associated with poor clinical
outcome after acute stroke.7
Clinical outcomes
The primary outcome was the modiﬁed Rankin Scale (mRS)
score,21 a 7-level ordered categorical scale (0 = independent, 6
= dead) measured at day 90. Secondary outcomes at day 90
included disability (Barthel Index), quality of life (health utility
status calculated with European Quality of Life 5-dimensions
3-level scale and visual analog scale), mood (Zung Depression
Scale), and cognition (telephone Mini-Mental State Examina-
tion [t-MMSE],22 modiﬁed Telephone Interview for Cognitive
Status [TICS-M],23 and verbal ﬂuency [animal naming]). In
essence, t-MMSE and TICS-M assess attention and memory,
while verbal ﬂuency assesses executive function. Participants
who died by day 90 were assigned the worst score for these
outcomes.24 Safety outcomes included all-causemortality, early
neurologic deterioration (reduction of ≥5 points or reduction
in the consciousness domain of >2 points from baseline to day
7 on the Scandinavian Stroke Scale [SSS]), and symptomatic
hypotension. Day 90 outcomes were assessed by trained blin-
ded assessors via telephone at national coordinating centers.
Statistical analysis
Data were analyzed by intention to treat16 and are given as
number (percent), median (interquartile range), or mean
(SD). Diﬀerences in baseline characteristics were assessed
with the χ2 test for categorical variables and 1-way analysis of
variance for continuous variables.
Diﬀerences between treatment group (GTN vs no GTN)
eﬀects on outcome were assessed with binary logistic re-
gression, multiple linear regression, ordinal logistic regression,
or Cox proportional hazard regression. Associations between
baseline imaging characteristics and mRS scores and cognitive
outcomes at day 90 were assessed with ordinal logistic re-
gression and multiple linear regression, respectively. Statisti-
cal models were adjusted for baseline prognostic covariates,
including age, sex, baseline mRS score, history of stroke,
history of diabetes mellitus, ﬁnal diagnosis, nitrate use, base-
line systolic blood pressure, baseline SSS score, thrombolysis,
feeding status, time to randomization, and treatment alloca-
tion (GTN vs no GTN and/or continue vs stop prestroke
antihypertensives). Results are reported as odds ratio (OR) or
mean diﬀerence (MD) and associated 95% conﬁdence
intervals (CIs) or standardized regression coeﬃcient (β) with
signiﬁcance deﬁned as p ≤ 0.05. Analyses were performed with
SPSS version 24 (SPS Inc, Chicago, IL).
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request. Sup-
plementary data are available from Dryad (tables 6–8 and
ﬁgures 3–5, doi.org/10.5061/dryad.6552r2b).
Results
A total of 1,397 of 4,011 (34.8%) patients with LACS were
recruited into ENOS. Baseline characteristics of LACS dif-
fered from those presenting with non-LACS (table 1): com-
pared to participants without LACS, those with LACS were
younger (67.9 [12.0] years); more were male (61.1%),
recruited in Asia, had diabetes mellitus, or were smokers; and
they were less dependent at baseline, with less prestroke hy-
pertension, TIA, hyperlipidemia, ischemic heart disease, pe-
ripheral arterial disease, or atrial ﬁbrillation. Participants with
LACS also had milder index events (mean SSS score 42 vs 29,
p < 0.001) and a longer time to randomization, and fewer
received thrombolysis than participants without LACS. Most
participants (92%) were imaged with CT. At baseline, there
were more acute lacunar infarctions and fewer acute hemor-
rhages in those with LACS than in those with non-LACS,
while background changes—leukoaraiosis, cerebral atrophy
and old vascular lesions—did not diﬀer between the groups
(data available from Dryad, table 6, doi.org/10.5061/dryad.
6552r2b). In participants with LACS, 50% had moderate or
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Table 1 Baseline clinical characteristics
All Non-LACS
LACS LACS and compatible scan LACS and acute lacunar infarct
All p Value GTN No GTN All GTN No GTN All GTN No GTN
Patients, n 4,011 2,614 1,397 695 702 623 308 315 143 71 72
Age, y 70.3 (12.2) 71.6 (12) 67.9 (12) <0.001 67.8 (12.2) 68.1 (12.1) 68.7 (11.6) 68.2 (11.7) 69.0 (11.5) 66.8 (10.9) 65.5 (11.5) 68.0 (10.2)
Male, n (%) 2,297 (57.3) 1444 (55.2) 853 (61.1) <0.001 424 (61) 429 (61.1) 395 (63.4) 185 (60.1) 210 (66.7) 84 (58.7) 41 (57.7) 43 (59.7)
Geographic region, n (%)
Asia 559 (13.9) 276 (10.6) 283 (20.3) <0.001 140 (20.1) 143 (20.4) 107 (17.2) 57 (18.5) 50 (15.9) 46 (32.2) 23 (32.4) 23 (31.9)
Europe 647 (16.1) 409 (15.6) 238 (20.3) 0.25 118 (17) 120 (17.1) 125 (20.1) 62 (20.1) 63 (20.0) 17 (11.9) 10 (14.1) 7 (9.7)
United Kingdom 2,545 (63.5) 1741 (66.6) 804 (57.6) <0.001 399 (57.4) 405 (57.7) 359 (57.6) 172 (55.8) 187 (59.4) 75 (52.4) 35 (49.3) 40 (55.6)
mRS score >0, n (%) 1026 (25.6) 733 (28) 293 (21) <0.001 134 (19.3) 159 (22.6) 130 (20.9) 62 (20.1) 68 (21.6) 28 (19.6) 14 (19.7) 14 (19.4)
Medical history, n (%)
Hypertension 2,607 (65) 1768 (67.6) 839 (60.1) <0.001 405 (58.3) 434 (61.8) 364 (58.4) 175 (56.8) 189 (60.0) 80 (55.9) 41 (57.7) 39 (54.2)
Diabetes mellitus 699 (17.4) 427 (16.3) 272 (19.5) 0.013 134 (19.3) 138 (19.7) 137 (22.0) 68 (22.1) 69 (21.9) 36 (25.2) 22 (31) 14 (19.4)
Atrial fibrillation 762 (19) 626 (23.9) 136 (9.7) <0.001 63 (9.1) 73 (10.4) 54 (8.7) 29 (9.4) 25 (7.9) 4 (2.8) 3 (4.2) 1 (1.4)
Prior stroke 594 (14.8) 406 (15.5) 188 (13.5) 0.08 96 (13.8) 92 (13.1) 79 (12.7) 38 (12.3) 41 (13.0) 19 (13.3) 10 (14.1) 9 (12.5)
Prior TIA 544 (13.6) 387 (14.8) 157 (11.2) 0.001 83 (11.9) 74 (10.5) 77 (12.4) 40 (13.0) 37 (11.7) 16 (11.2) 9 (12.7) 7 (9.7)
Prior IHD 669 (16.7) 467 (17.9) 202 (14.5) 0.002 97 (14) 105 (15) 96 (15.4) 47 (15.3) 49 (15.6) 17 (11.9) 7 (9.9) 10 (13.9)
Prior PAD 117 (2.9) 79 (3) 38 (2.7) 0.040 16 (2.3) 22 (3.1) 19 (3.0) 9 (2.9) 10 (3.2) 3 (2.1) 1 (1.4) 2 (2.8)
Hyperlipidemia 1098 (27.4) 759 (29) 339 (24.3) <0.001 173 (24.9) 166 (23.6) 155 (24.9) 83 (26.9) 72 (22.9) 34 (23.8) 16 (22.5) 18 (25)
Smoking, current 945 (23.6) 566 (21.7) 379 (27.1) <0.001 186 (26.8) 193 (27.5) 181 (29.1) 90 (29.2) 91 (28.9) 50 (35) 23 (32.4) 27 (37.5)
Nitrate 154 (3.8) 115 (4.4) 39 (2.8) 0.012 22 (3.2) 17 (2.4) 10 (1.6) 8 (2.6) 2 (0.6) 1 (0.7) 0 1 (1.4)
Alcohol >21 units/wk 294 (7.3) 185 (7.1) 109 (7.8) 0.40 56 (8.1) 53 (7.5) 43 (6.9) 19 (6.2) 24 (7.6) 10 (7) 4 (5.6) 6 (8.3)
Qualifying event
Ischemic stroke, n (%) 3,342 (83.3) 2,162 (82.7) 1180 (84.5) 0.16 584 (84) 596 (84.9) 623 (100) 308 (100) 315 (100) 143 (100) 71 (100) 72 (100)
Hemorrhagic stroke, n (%) 629 (15.7) 429 (16.4) 200 (14.3) 0.08 100 (14.4) 100 (14.2) 0 0 0 0 0 0
SSS score (of 58) 33.7 (13.2) 29.4 (13.5) 41.7 (7.9) <0.001 41.9 (8.0) 41.6 (7.7) 42.9 (7.4) 43.1 (7.5) 42.8 (7.3) 42.4 (7.9) 42.9 (7.4) 42.0 (8.4)
NIHSS score (of 42), calculated 11.2 (5.7) 13 (5.8) 7.7 (3.4) <0.001 7.7 (3.4) 7.8 (3.3) 7.2 (3.2) 7.2 (3.2) 7.3 (3.2) 7.4 (3.4) 7.3 (3.2) 7.6 (3.6)
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severe cerebral atrophy, 41% had some degree of leukoar-
aiosis, and 61% had an old vascular lesion. SVD and brain
frailty scores were moderately positively correlated (Spear-
man correlation coeﬃcient 0.626, p < 0.001).
Imaging and functional outcome
The associations between baseline imaging characteristics and
mRS score at day 90 were assessed in all participants (n =
3,995), those with LACS (n = 1,392), those with LACS and
a compatible scan (n = 623), and those with LACS with an
acute lacunar infarction (n = 143) (table 2). In the whole
population, visible infarction, cerebral atrophy score, leukoar-
aiosis score, old lacunar infarct/lacune, and old striatocapsular
infarct were individually associated with unfavorable shifts in
mRS score at day 90. In participants with LACS, parenchymal
hemorrhage, cerebral atrophy score, leukoaraiosis score, old
lacunar infarct/lacune, and old striatocapsular infarct were in-
dividually associated with unfavorable shifts in mRS score at
day 90. In those with LACS and a compatible scan, cerebral
atrophy, old lacunar infarct/lacune, and old striatocapsular in-
farct were individually associated with unfavorable shifts in
mRS score at day 90. In those with LACS and acute lacunar
infarction, no individual imaging features were associated with
mRS score at day 90.
Increasing SVD score was associated with unfavorable shifts in
mRS score at day 90 in the whole ENOS population, those
with LACS, and those with LACS and a compatible scan. Each
1-point increase in SVD score was associated with an in-
creased odds of shift in the mRS score to more death or
dependency, with increasing eﬀect sizes present with in-
creasing speciﬁcity of lacunar stroke diagnosis: whole ENOS
population OR 1.15 (95% CI 1.07–1.24), LACS OR 1.30
(95% CI 1.15–1.47), LACS and a compatible scan OR 1.43
(95% CI 1.19–1.72), and LACS with acute lacunar infarction
OR 1.45 (95% CI 1.00–2.11) (table 2). Removing atrophy
from the SVD score resulted in comparable associations with
outcome (data not shown). In a multivariate ordinal re-
gression assessing the association between individual features
comprising the SVD score and functional outcome in the
whole ENOS population, all features had similar eﬀect sizes
within the model: severe leukoaraiosis OR 1.17 (95% CI
0.99–1.38), severe atrophy OR 1.12 (95% CI 0.99–1.27), and
old lacunar infarcts/lacunes OR 1.17 (95% CI 1.04–1.32).
However, with increasing speciﬁcity of lacunar stroke di-
agnosis, the eﬀect sizes for severe atrophy and old lacunar
infarcts/lacunes increased, while severe leukoaraiosis did not
(severe atrophy: LACS OR 1.35 [95% CI 1.10–1.67], LACS
and a compatible scan OR 1.39 [95% CI 1.02–1.89]; old
lacunar infarcts/lacunes: LACS OR 1.31 [95% CI 1.07–1.61],
LACS and a compatible scan OR 1.67 [95% CI 1.23–2.25]).
Increased brain frailty features were associated with worse
functional outcome at 90 days (ﬁgure 1) in the whole ENOS
population (OR 1.25, 95%CI 1.17–1.34), in those with LACS
(OR 1.28, 95% CI 1.14–1.44), and in those with LACS and
a compatible scan (OR 1.29, 95% CI 1.08–1.53), but not inTa
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Table 2 Associations between baseline imaging characteristics and primary outcome (mRS score at day 90)
Overall LACS LACS and compatible scan LACS and acute lacunar infarct
n (%) OR (95% CI) p Value n (%) OR (95% CI) p Value n (%) OR (95% CI) p Value n (%) OR (95% CI) p Value
No. 3,995 — — 1,392 — — 623 — — 143 — —
Visible infarction 2041
(50.9)
1.14 (1.01, 1.28) 0.030 658
(47.1)
1.17 (0.94, 1.45) 0.15 144
(24.1)
0.98 (0.69, 1.38) 0.91 143
(100)
— —
Lacunar 241 (6.4) 0.83 (0.66, 1.05) 0.13 143
(11.0)
0.83 (0.60, 1.13) 0.24 143
(24.0)
0.97 (0.68, 1.37) 0.85 143
(100)
— —
Visible hemorrhage 673
(16.8)
1.10 (0.95, 1.29) 0.20 197
(14.1)
1.22 (0.93, 1.61) 0.15 0 — — 0 — —
Parenchymal hemorrhage 587
(14.6)
1.11 (0.95, 1.31) 0.19 184
(14.1)
1.38 (1.01, 1.89) 0.041 0 — — 0 — —
Lobar or cerebellar 79 (2.1) 1.46 (0.98, 2.18) 0.07 25 (1.9) 0.84 (0.41, 1.71) 0.63 0 — — 0 — —
Deep 507
(13.4)
1.06 (0.89, 1.25) 0.52 158
(12.1)
1.34 (0.99, 1.82) 0.057 0 — — 0 — —
Cerebral atrophy score (of 4),
median (IQR)
2 (2) 1.14 (1.09, 1.21) <0.001 2 (2) 1.23 (1.13, 1.35) <0.001 2 (2) 1.16 (1.02, 1.32) 0.028 2 (3) 1.12 (0.88, 1.42) 0.83
Leukoaraiosis score (of 4), median
(IQR)
0 (2) 1.11 (1.07, 1.16) <0.001 0 (2) 1.11 (1.03, 1.19) 0.007 0 (2) 1.10 (0.98, 1.23) 0.11 1 (2) 1.15 (0.91, 1.45) 0.24
Old infarcts
Striatocapsular 585
(15.2)
1.29 (1.10, 1.51) 0.002 210
(15.8)
1.51 (1.15, 1.97) 0.003 114
(18.3)
1.82 (1.25, 2.64) 0.002 14 (9.8) 1.69 (0.62, 4.65) 0.31
Border zone 74 (1.9) 1.35 (0.89, 2.04) 0.15 26 (2.0) 0.69 (0.35, 1.39) 0.31 9 (1.4) 0.52 (0.16, 1.71) 0.28 4 (2.8) 0.26 (0.04, 1.65) 0.15
Lacunar 1423
(37.0)
1.19 (1.06, 1.35) 0.003 514
(38.6)
1.35 (1.11, 1.65) 0.003 249
(40.0)
1.70 (1.26, 2.29) 0.001 68
(47.6)
1.43 (0.77, 2.64) 0.26
At least 1 of above 1619
(42.1)
1.21 (1.08, 1.36) 0.001 588
(44.1)
1.35 (1.11, 1.65) 0.003 284
(45.6)
1.76 (1.31, 2.36) <0.001 71
(49.7)
1.31 (0.71, 2.40) 0.38
SVD score (of 3), median (IQR) 1 (2) 1.15 (1.07, 1.24) <0.001 1 (2) 1.30 (1.15, 1.47) <0.001 1 (2) 1.43 (1.19, 1.72) <0.001 1 (2) 1.45 (1.00, 2.11) 0.051
Brain frailty score (of 3), median
(IQR)
2 (2) 1.25 (1.17, 1.34) <0.001 2 (2) 1.28 (1.14, 1.44) <0.001 2 (2) 1.29 (1.08, 1.53) 0.005 2 (2) 1.16 (0.84, 1.60) 0.35
Abbreviations: CI = confidence interval; IQR = interquartile range; LACS = lacunar syndrome; mRS = modified Rankin Scale; OR = odds ratio; SVD = small vessel disease.
Data are number (percent) or median (IQR). SVD score comprises severe anterior or posterior leukoaraiosis, any old lacunar infarcts, severe central, or cortical atrophy (maximum 3 of 3). Brain frailty score comprises
leukoaraiosis, cerebral atrophy, and old vascular lesions (maximum 3 of 3). The OR represents an ordinal logistic regression analysis of shift in the mRS score with adjustment for age, sex, baseline Scandinavian Stroke Scale
score, and time to randomization.
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the small group of LACS with an acute lacunar infarct. Hence,
a 1-point increase in brain frailty score was associated with
a similar increased odds of shift to more death or dependency
across the 3 populations. In a multivariate ordinal regression
assessing the association between individual features com-
prising brain frailty and functional outcome in the whole
ENOS population, all features had similar eﬀect sizes within
the model: leukoaraiosis OR 1.10 (95% CI 1.05–1.15), atro-
phy OR 1.12 (95% CI 1.06–1.19), and old vascular lesions/
infarcts OR 1.14 (95% CI 1.01–1.29). Unlike with the SVD
score, we did not see any consistent changes in the eﬀect sizes
for the individual features comprising the brain frailty score as
we progressed through the lacunar stroke hierarchy.
MRI data were available for 109 participants with LACS. Only
old lacunar infarcts/lacunes were associated with an un-
favorable shift in mRS score at day 90 (data available from
Dryad, table 7, doi.org/10.5061/dryad.6552r2b).
Imaging and cognitive outcomes
Day 90 cognitive outcomes were available in about half of the
overall population: t-MMSE in 1,949 (49%, table 3), TICS-M
in 1,930 (48%, table 4), and verbal ﬂuency in 2,269 (57%,
table 5). Participants with no cognitive data at 90 days were
older (73 [16] vs 71 [18] years) and had more severe strokes
(baseline mean SSS score 35 vs 32, p < 0.001) than those with
at least 1 telephone cognitive assessment.
Overall, visible infarction, cerebral atrophy score, and leu-
koaraiosis score were independently associated with worse
cognitive scores on t-MMSE and TICS-M at 90 days (data
available from Dryad, ﬁgures 3 and 4, doi.org/10.5061/dryad.
6552r2b). In addition, acute lacunar infarction, parenchymal
and deep hemorrhage, and old lacunar infarct/lacunewere each
associated independently with worse verbal ﬂuency scores at 90
days. Brain frailty was associated with worse scores on all 3
cognitive measures (ﬁgure 2). Those with baseline brain frailty
scores of 3 had worse cognitive scores compared to those with
no evidence of brain frailty (t-MMSE: MD −1.13, 95% CI
−2.37 to 0.11, p = 0.07; TICS-M: MD −2.49, 95% CI −4.25 to
−0.73, p = 0.006; verbal ﬂuency: MD −1.72, 95% CI −2.97 to
−0.46, p = 0.008). Inmultivariate linear regression assessing the
association between individual features comprising brain frailty
and cognition, leukoaraiosis, and atrophy were consistently
associated with worse cognition across all 3 measures, while old
vascular lesions/infarcts were not. In contrast to brain frailty,
SVD score was associated with worse verbal ﬂuency only: those
with an SVD score of 3 had lower verbal ﬂuency scores com-
pared to those with an SVD score of 0 (MD −2.12, 95% CI
−3.66 to −0.58, p = 0.007, data available from Dryad ﬁgure 5,
doi.org/10.5061/dryad.6552r2b). In multivariate analyses
assessing the association between individual features of the
SVD score and cognitive outcomes, only severe leukoaraiosis
was associated with all 3 cognitive measures, while old lacunar
infarcts/lacunes were associated with worse verbal ﬂuency only.
In participants with LACS, leukoaraiosis and cerebral atrophy
scores were associated with worse cognitive scores on all 3
measures (tables 3–5). Brain frailty score was associated with
worse cognitive outcomes across all 3 domains. Those with
baseline brain frailty scores of 3 had worse cognitive scores
compared to those with no brain frailty (t-MMSE: MD −1.92,
95% CI −3.89 to 0.06, p = 0.057; TICS-M: MD −4.26, 95% CI
Figure 1 mRS score at day 90 by brain frailty score on
baseline imaging
Boxplots of modified Rankin Scale (mRS) score at day 90 by brain frailty
score in (A) thewhole Efficacy ofNitric Oxide in Stroke (ENOS) population (n =
3,995), (B) participants with lacunar syndrome (LACS, n = 1392), and (C)
participants with LACS with compatible scan (n = 623).
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−7.17 to −1.36, p = 0.004; verbal ﬂuency: MD −3.81, 95% CI
−6.11 to −1.51, p = 0.001). As in the whole ENOS population,
in multivariate linear regression models, the individual brain
frailty markers leukoaraiosis and atrophy were consistently
associated with worse cognition across all 3 measures, while old
vascular lesions/infarcts were not. SVD score was associated
with worse verbal ﬂuency only (tables 3–5), which in multi-
variate analyses seemed to be driven by the eﬀect of old lacunar
infarcts/lacunes rather than severe leukoaraiosis or severe
atrophy.
In those with LACS and a compatible scan, leukoaraiosis score
was associated with worse t-MMSE and TICS-M scores, while
cerebral atrophy score was associated with worse verbal ﬂu-
ency scores only. Brain frailty score was associated with worse
t-MMSE and TICS-M scores but was not signiﬁcantly asso-
ciated with verbal ﬂuency. SVD scores were not associated
with cognitive outcomes in this small population (tables 3–5).
There were insuﬃcient cognitive data for analysis in those
with LACS and an acute lacunar infarction (n = 60).
GTN and lacunar stroke
GTN had no eﬀect on mRS score at day 90 compared with no
GTN in those with LACS (OR 1.07, 95% CI 0.88–1.29, n =
1392), LACS and compatible scan (OR 1.09, 95%CI 0.82–1.45,
Table 3 Associations between baseline imaging characteristics and t-MMSE score at day 90
Overall LACS LACS and compatible scan
n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value
No. 1,949 — — 719 — — 313 — —
Visible infarction 996
(51.1)
−0.75 (−1.29,
−0.22)
0.006 327
(47.3)
−0.24 (−1.06,
0.58)
0.56 39
(12.6)
−0.35 (−2.23,
1.53)
0.71
Lacunar 81
(4.2)
−0.70 (−2.06,
0.67)
0.32 39
(5.6)
0.06 (−1.84,
1.96)
0.95 39
(12.6)
−0.35 (−2.23,
1.53)
0.71
Visible hemorrhage 336
(17.1)
−0.61 (−1.34,
0.13)
0.11 90
(12.9)
−0.95 (−2.20,
0.30)
0.64 0 — —
Parenchymal
hemorrhage
296
(15.2)
−0.42 (−1.20,
0.36)
0.29 84
(12.2)
−0.62 (−1.91,
0.66)
0.34 0 — —
Lobar or cerebellar 52
(2.7)
−0.05 (−1.67,
1.57)
0.95 15
(2.2)
1.03 (−1.85,
3.92)
0.48 0 — —
Deep 243
(12.5)
−0.42 (−1.30,
0.45)
0.34 68
(9.8)
−1.08 (−2.50,
0.33)
0.13 0 — —
Cerebral atrophy score
(of 4), median (IQR)a
2 (2) −0.045 0.026 2 (2) −0.094 0.023 2 (1) −0.066 0.29
Leukoaraiosis score
(of 4), median (IQR)a
0 (2) −0.085 <0.001 0 (2) −0.129 <0.001 0 (2) −0.141 0.013
Old infarcts
Striatocapsular 316
(16.1)
0.31 (−0.42,
1.04)
0.41 129
(18.6)
0.07 (−1.01,
1.15)
0.90 66
(21.1)
−0.69 (−2.21,
0.82)
0.37
Border zone 35
(1.8)
−0.72 (−2.80,
1.35)
0.49 11
(1.6)
−0.94 (−4.27,
2.39)
0.58 3 (1.0) 0.40 (−5.52,
6.32)
0.89
Lacunar 764
(38.8)
−0.26 (−0.81,
0.29)
0.36 282
(40.6)
0.03 (−0.84,
0.90)
0.95 123
(39.3)
0.16 (−1.16,
1.47)
0.82
At least 1 of above 859
(43.7)
−0.14 (−0.68,
0.41)
0.62 323
(46.5)
−0.05 (−0.90,
0.80)
0.91 145
(46.3)
−0.58 (−1.86,
0.69)
0.37
SVD score (of 3),
median (IQR)a
1 (2) −0.016 0.40 1 (2) −0.042 0.29 1 (1) −0.060 0.33
Brain frailty score (/3),
median (IQR)a
2 (2) −0.062 0.002 2 (2) −0.096 0.018 2 (2) −0.157 0.013
Abbreviations: CI = confidence interval; IQR = interquartile range; LACS = lacunar syndrome; MD = mean difference; SVD = small vessel disease; t-MMSE =
telephone Mini-Mental State Examination.
SVD score comprises severe anterior or posterior leukoaraiosis, any old lacunar infarcts, and severe central or cortical atrophy (maximum3 of 3). Brain frailty
score comprises leukoaraiosis, cerebral atrophy, and old vascular lesions (maximum 3 of 3). Multiple linear regression with adjustment for age, sex, baseline
Scandinavian Stroke Scale score, and time to randomization.
a Standardized regression coefficient reported.
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n = 623), or LACS and acute lacunar infarction (OR 1.00, 95%
CI 0.53–1.87, n = 143). GTNwithin 6 hours did not change any
day 90 clinical outcomes in lacunar stroke populations (data
available from Dryad, table 8, doi.org/10.5061/dryad.6552r2b).
Furthermore, in 339 participants with LACS, GTN did not
inﬂuence imaging markers at day 7 (data not shown).
Discussion
In this large population of patients with lacunar stroke syn-
dromes randomized into the ENOS trial, baseline imaging
markers of SVD and brain frailty were common and associated
with poor functional and cognitive outcomes at 90 days, in-
dividually and in combination. Themagnitude of SVD and brain
frailty was similar in those with lacunar and nonlacunar stroke
despite the patients with lacunar stroke being younger. Fur-
thermore, the strength of association of SVD score with poor
functional outcome increased with increasing speciﬁcity of la-
cunar stroke diagnosis, while brain frailty had similar associa-
tions across the trial population. GTN did not alter functional
outcome of patients with acute stroke presenting with LACS.
Prestroke TIA, ischemic heart disease, peripheral arterial
disease, and atrial ﬁbrillation were all less common in partic-
ipants with lacunar stroke than in those with nonlacunar
Table 4 Associations between baseline imaging characteristics and TICS-M score at day 90
Overall LACS LACS and compatible scan
n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value
No. 1,930 — — 686 — — 308 — —
Visible infarction 987
(51.1)
−0.84 (−1.60,
−0.08)
0.031 326
(47.5)
−0.23 (−1.45,
0.98)
0.71 38 (12.3) 0.88 (−1.98,
3.73)
0.55
Lacunar 80
(4.1)
−0.57 (−2.51,
1.38)
0.57 38
(5.5)
1.20 (−1.62,
4.02)
0.41 38 (12.3) 0.88 (−1.98,
3.73)
0.55
Visible hemorrhage 331
(17.0)
−0.72 (−1.77,
0.33)
0.18 88
(12.8)
−0.55 (−2.40,
1.31)
0.56 0 — —
Parenchymal
hemorrhage
292
(15.1)
−0.35 (−1.46,
0.76)
0.53 82
(12.0)
−0.11 (−2.03,
1.80)
0.91 0 — —
Lobar or cerebellar 52
(2.7)
0.70 (−1.60,
2.99)
0.55 15
(2.2)
1.53 (−2.74,
5.80)
0.48 0 — —
Deep 239
(12.4)
−0.56 (−1.80,
0.68)
0.38 66
(9.6)
−0.66 (−2.78,
1.45)
0.54 0 — —
Cerebral atrophy
score
(of 4), median (IQR)a
2 (2) −0.068 0.001 2 (2) −0.137 0.001 2 (1) −0.095 0.12
Leukoaraiosis score
(of 4), median (IQR)a
0 (2) −0.088 <0.001 0 (2) −0.124 0.001 0 (2) −0.131 0.018
Old infarcts
Striatocapsular 310
(15.9)
0.29 (−0.76,
1.33)
0.59 126
(18.3)
−0.42 (−2.09,
1.19)
0.61 64 (20.6) −1.41 (−3.71,
0.89)
0.23
Border zone 35
(1.8)
−0.79 (−3.73,
2.15)
0.60 11
(1.6)
−1.89 (−6.79,
3.01)
0.45 3 (1.0) 1.03 (−7.85,
9.91)
0.82
Lacunar 758
(38.9)
−0.55 (−1.33,
0.24)
0.17 279
(40.4)
−0.52 (−1.81,
0.77)
0.43 121
(38.9)
−0.14 (−2.13,
1.86)
0.89
At least 1 of above 850
(43.6)
−0.38 (−1.16,
0.39)
0.33 319
(46.2)
−0.54 (−1.80,
0.72)
0.40 143
(46.0)
−0.85 (−2.78,
1.07)
0.38
SVD score (of 3),
median (IQR)a
1 (2) −0.024 0.21 1 (2) −0.063 0.10 1 (1) −0.063 0.29
Brain frailty score (of
3), median (IQR)a
2 (2) −0.080 <0.001 2 (2) −0.133 0.001 2 (2) −0.187 0.003
Abbreviations: CI = confidence interval; IQR = interquartile range; LACS = lacunar syndrome; MD = mean difference; SSS = Scandinavian Stroke Scale; SVD =
small vessel disease; TICS-M = modified Telephone Interview for Cognitive Status.
SVD score comprises severe anterior or posterior leukoaraiosis, any old lacunar infarcts, and severe central or cortical atrophy (maximum 3 of 3). Brain frailty
score comprises leukoaraiosis, cerebral atrophy, and old vascular lesions (maximum 3 of 3). Multiple linear regression with adjustment for age, sex, baseline
SSS score, and time to randomization.
a Standardized regression coefficient reported.
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strokes, supporting previous studies demonstrating that large
artery disease and cardioembolic sources are important risk
factors for nonlacunar, but less so for lacunar ischemic
strokes.19,25,26 While smoking and diabetes mellitus were
more common in our lacunar than nonlacunar stroke pop-
ulation,4 perhaps surprisingly, those with LACS had less hy-
pertension and hyperlipidemia than those with non-LACS,
although this ﬁnding is in keeping with previous data showing
that traditional vascular risk factors, when combined, account
for <2% of the variance in SVD features in patients with stroke
and healthy older populations.26
In line with our results, SVD scores and their component im-
aging ﬁndings have been associated with adverse clinical
outcomes after stroke in 4 other smaller cohorts. Data from the
Stroke Imaging Repository (STIR)/Virtual International Stroke
Trials Archive (VISTA) showed that severe leukoaraiosis and
total SVD score on MRI in 259 patients with ischemic stroke
treated with thrombolysis were associated with increased dis-
ability and functional dependency at 90 days.9 In contrast,
lacunes, cerebral atrophy, and enlarged perivascular spaces were
not individually associated with clinical outcome, probably be-
cause of a lack of power. A retrospective cohort involving 1,026
participants using MRI data found an association between SVD
score and all-cause and stroke-related mortality.27 SVD burden
onMRI has also been associated with worse quality-of-life scores
3 months after acute ischemic stroke28 and decreased cognitive
function over 4 years in patients with ﬁrst-ever lacunar ischemic
Table 5 Associations between baseline imaging characteristics and verbal fluency at day 90
Overall LACS LACS and compatible scan
n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value n (%) MD (95% CI)/β p Value
No. 2,269 — — 818 — — 366 — —
Visible infarction 1176
(51.8)
−0.72 (−1.29,
−0.15)
0.013 395
(48.3)
−0.79 (−1.82,
0.23)
0.13 60
(16.4)
−1.97 (−4.11,
0.17)
0.07
Lacunar 118
(5.2)
−1.32 (−2.60,
−0.04)
0.043 60
(7.3)
−1.13 (−3.09,
0.84)
0.26 60
(16.4)
−1.97 (−4.11,
0.17)
0.07
Visible hemorrhage 406
(17.7)
−0.97 (−1.73,
−0.21)
0.013 115
(14.0)
−1.39 (−2.88,
0.10)
0.07 0 — —
Parenchymal
hemorrhage
361
(15.9)
−0.87 (−1.67,
−0.07)
0.033 108
(13.2)
−1.28 (−2.81,
0.26)
0.10 0 — —
Lobar or cerebellar 57
(2.5)
1.15 (−0.62,
2.92)
0.20 16
(2.0)
2.35 (−1.51,
6.20)
0.23 0 — —
Deep 303
(13.4)
−1.22 (−2.10,
−0.34)
0.006 91
(11.1)
−2.00 (−3.65,
−0.36)
0.017 0 — —
Cerebral atrophy score
(of 4), median (IQR)a
2 (2) −0.075 <0.001 2 (2) −0.136 <0.001 2 (2) −0.127 0.028
Leukoaraiosis score
(of 4), median (IQR)a
0 (2) −0.095 <0.001 0 (2) −0.109 0.002 0 (2) −0.073 0.18
Old infarcts
Striatocapsular 347
(15.2)
−0.34 (−1.13,
0.45)
0.39 139
(16.9)
−0.11 (−1.49,
1.26)
0.87 71
(19.2)
−0.81 (−2.87,
1.24)
0.44
Border zone 42
(1.8)
−1.49 (−3.66,
0.69)
0.18 14
(1.7)
−4.04 (−8.03,
−0.06)
0.047 5
(1.4)
−5.12 (−11.69,
1.45)
0.13
Lacunar 867
(37.9)
−0.95 (−1.54,
−0.37)
0.001 322
(39.1)
−1.16 (−2.23,
−0.08)
0.035 142
(38.4)
−1.94 (−3.65,
−0.23)
0.026
At least 1 of above 968
(42.3)
−0.84 (−1.42,
−0.27)
0.004 365
(44.3)
−1.02 (−2.07,
0.03)
0.058 165
(44.6)
−1.96 (−3.62,
−0.29)
0.022
SVD score (of 3),
median (IQR)a
1 (2) −0.061 0.001 1 (2) −0.086 0.019 1 (1) −0.105 0.07
Brain frailty score (of
3), median (IQR)a
2 (2) −0.096 <0.001 2 (2) −0.140 <0.001 2 (2) −0.108 0.07
Abbreviations: CI = confidence interval; IQR = interquartile range; LACS = lacunar syndrome; MD = mean difference; SSS = Scandinavian Stroke Scale; SVD =
small vessel disease.
Data are mean (SD). SVD score comprises severe anterior or posterior leukoaraiosis, any old lacunar infarcts, and severe central or cortical atrophy
(maximum3of 3). Brain frailty score comprises leukoaraiosis, cerebral atrophy, and old vascular lesions (maximum3of 3).Multiple linear regression ofMD in
scores, with adjustment for age, sex, baseline SSS score, and time to randomization.
a Standardized regression coefficient reported.
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stroke and hypertension.29 In the present analysis, SVD scores
with and without atrophy showed similar associations with
functional outcome at 90 days overall and in the lacunar stroke
populations, suggesting that the main drivers for functional
outcome were the vascular rather than the associated neurode-
generative imaging features. The strength of association of SVD
score with worse functional outcome increased with increasing
speciﬁcity of lacunar stroke diagnosis.
We conﬁrm the important prognostic value of the 3 brain
frailty measures on CT of leukoaraiosis, atrophy, and old
vascular lesions that were each independently associated with
poor outcome in IST-3.7 Furthermore, we have demonstrated
that pooling these imaging markers in a score including any
old infarct (not just lacunes as in the SVD score) was asso-
ciated with functional and cognitive outcomes 90 days after
stroke; in contrast to the SVD score, brain frailty showed
a similar strength of association with poor functional outcome
across non-LACS and LACS populations. Although SVD and
brain frailty scores were moderately positively correlated and
measure similar imaging markers, the diﬀerences in severity of
the individual markers included provide 2 diﬀerent ways of
assessing brain health. This is supported by their diﬀering
eﬀects on clinical outcomes and the diﬀerent contribution of
the individual features in multivariate regression models.
There were interesting diﬀerences in associations between
imaging features and performance in the diﬀerent cognitive
domains. In the whole ENOS population, several acute and
prestroke imaging features were associated with impairment in
all cognitive domains. However, the SVD score added little
compared with leukoaraiosis alone, which tended to be asso-
ciated with verbal ﬂuency, whereas brain frailty score was as-
sociated with all cognitive impairments. This may reﬂect the
known eﬀects of white matter lesions on processing speed and
of brain atrophy (as a sign of neurodegeneration) on memory;
alternatively, it could reﬂect a lack of statistical power due to
missing cognitive data. Furthermore, these ﬁndings suggest that
imaging signs may have diﬀerential relationships with cognition
and its domains in diﬀerent stroke subtypes; this emphasizes
the importance of testing all cognitive domains in future re-
search and that some cognitive tests may be insensitive to the
types of impairment speciﬁc to particular stroke types.
These imaging markers are easy to detect on plain CT by
physicians and radiologists in acute stroke and, given their
strong prognostic signiﬁcance, may prove useful for predicting
outcome when added to clinical markers in clinical practice.
Whether brain frailty on imaging correlates with clinical frailty
is unclear, although these features correlate with gait, bal-
ance,6 and cognitive impairments,5 implying that a correlation
with clinical frailty is likely; thus, these brain features may
prove to be useful surrogate markers. For future acute stroke
clinical trials, minimization based on baseline imaging mark-
ers of brain frailty could be important to balance these
prognostic variables between treatment groups.
The favorable eﬀect of GTN given within 6 hours on stroke
onset30,31 was not seen in this analysis of participants with
LACS. The Rapid Intervention With Glyceryl Trinitrate in
Hypertensive Stroke Trial–2 (RIGHT-2, ISRCTN26986053)
will provide further detail on whether the eﬀects of GTN vary
between diﬀering stroke etiologies, with imaging markers
being key secondary outcomes.32,33 In addition, the longer-
term administration of isosorbide mononitrate (a long-acting
nitrate) is being assessed for safety and eﬃcacy in patients
Figure 2 Cognitive scores at day 90 by brain frailty score on
baseline imaging
Boxplots of cognitive scores—(A) telephone Mini-Mental State Examination
(t-MMSE, n = 1,949), (B) modified Telephone Interview for Cognitive Status
(TICS-M, n = 1,930), and (C) verbal fluency (n = 2,269)—at day 90 by brain
frailty in the whole Efficacy of Nitric Oxide in Stroke (ENOS) population.
Lower cognitive scores indicate worse cognition.
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with lacunar ischemic stroke and SVD in the ongoing Lacunar
Intervention Trial-2 (LACI-2, ISRCTN14911850).
The strengths of this ENOS analysis include the largest
dataset of patients with acute lacunar stroke to date from
a high-ﬁdelity randomized controlled trial with near-complete
follow-up, blinded and standardized adjudication of imaging
by trained observers using a standardized proforma, ordinal
analysis of the mRS score to increase statistical power, and
generalizability to clinical practice through the predominant
use of CT imaging. However, there are important limitations.
First, no adjustment was made for multiplicity of testing.
Therefore, some of the results may, in part, be due to chance,
although the strength of associations seen mitigates the risks
of multiple testing. Second, the mean age in ENOS was lower
than that seen in many unselected clinical stroke populations,
although this is typical for lacunar stroke. This may have
attenuated the observed associations because brain frailty is
likely to be evenmore prevalent in an older population. Third,
ENOS recruited over a 12-year period in which clinical
practice changed. Thus, the time from baseline imaging to
stroke onset was longer than we would expect in current
stroke clinical practice but is still common in patients with
minor stroke. Fourth, MRI, which is more sensitive to features
of SVD and acute infarction, was performed in only a small
proportion of ENOS participants. However, the predominant
use of CT enabled associations between SVD features visible
on CT and outcome to be assessed, which were found to be in
keeping with MRI-based studies and immediately applicable
in clinical practice. Fifth, clinical stroke syndrome classiﬁca-
tion with the OCSP was investigator reported and not adju-
dicated centrally. In addition, the OCSP is known to
misclassify ≈15% of lacunar strokes as partial anterior circu-
lation syndrome and cortical strokes as LACS, thus adding
noise to the data. We accounted for this in our more speciﬁc
lacunar stroke populations; this added to the generalizability
of the dataset and its ﬁndings to clinical practice. Sixth, tele-
phone cognition data were available for about half of partic-
ipants, largely because of stroke severity,24 limiting
generalizability. Finally, although trained neuroradiologists
adjudicated the imaging data, we cannot exclude interrater
and intrarater variability over the time scale of the trial.
We add to the increasing body of evidence that baseline im-
aging markers of SVD and brain frailty are common and as-
sociated with worse functional and cognitive outcomes at 90
days individually and when amalgamated as scores. Whether
the vascular or neurodegenerative features are more associated
with cognitive impairments requires further testing. CT imag-
ing features of brain frailty and SVD predict prognosis, should
be considered as components of minimization in clinical trials,
and may aid clinical decision-making in the future.
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